David Young - 05 Apr 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/s David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
05 Apr 2024
Net transactions value
-$1,927
Form type
4
Filing time
02 Aug 2024, 17:09:46 UTC
Previous filing
08 Feb 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Options Exercise +1,675 +2.1% 81,061 05 Apr 2024 Direct F1
transaction PCSA Common Stock Tax liability $1,445 -518 -0.64% $2.79 80,543 05 Apr 2024 Direct
transaction PCSA Common Stock Options Exercise +644 +0.8% 81,187 10 Jul 2024 Direct F1
transaction PCSA Common Stock Tax liability $482 -282 -0.35% $1.71 80,905 10 Jul 2024 Direct
holding PCSA Common Stock 30,985 05 Apr 2024 By Young-Plaisance Revocable Trust
holding PCSA Common Stock 10,786 05 Apr 2024 By Family Entities
holding PCSA Common Stock 18,544 05 Apr 2024 By CorLyst, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +3,233 +17% $0.000000 21,922 28 Jun 2024 Common Stock 3,233 $0.000000 Direct F2
transaction PCSA Restricted Stock Units Award $0 +2,425 +11% $0.000000 24,347 28 Jun 2024 Common Stock 2,425 $0.000000 Direct F3
transaction PCSA Restricted Stock Units Award $0 +404 +1.7% $0.000000 24,751 28 Jun 2024 Common Stock 404 $0.000000 Direct F4
transaction PCSA Restricted Stock Units Award $0 +404 +1.6% $0.000000 25,155 28 Jun 2024 Common Stock 404 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distribution of vested restricted shares.
F2 Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
F4 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.